Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction Its Role in Hypercholesterolemia
1998
Background—Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. Because endothelial NO elaboration is impaired in hypercholesterolemia, we investigated whether plasma concentrations of ADMA are elevated in young, clinically asymptomatic hypercholesterolemic adults. We further studied whether such elevation of ADMA levels was correlated with impaired endothelium-dependent, NO-mediated vasodilation and urinary nitrate excretion. In a randomized, double-blind, placebo-controlled study, we investigated whether these changes could be reversed with exogenous l-arginine. Methods and Results—We measured plasma levels of l-arginine, ADMA, and symmetrical dimethylarginine (SDMA) by high-performance liquid chromatography in 49 hypercholesterolemic (HC) and 31 normocholesterolemic (NC) humans. In 8 HC subjects, endothelium-dependent forearm vasodilation was assessed before and after an intravenous infusion of l-arginine or placebo and compared with 8 NC control subj...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
47
References
1120
Citations
NaN
KQI